<DOC>
	<DOC>NCT00533897</DOC>
	<brief_summary>The purpose of the study is to determine whether subcutaneous abatacept administered to patients with rheumatoid arthritis is associated with increased immunogenicity or increased safety events upon withdrawal and reintroduction.</brief_summary>
	<brief_title>Phase IIIB Subcutaneous Missed Dose Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Clinical diagnosis of Rheumatoid Arthritis Disease Activity Score (DAS)28CReactive Protein (CRP) score ≥ 3.2 and ≤5.1 On background methotrexate at least 3 months (≥10mg weekly) Must be able to self injection or allow a care giver to do it for them Discontinue all Biologics and DiseaseModifying Antirheumatic Drugs (DMARDs) except for methotrexate Participants who had prior exposure to abatacept or CTLA4 Ig Received treatment with rituximab. Participants who have received treatment with leflunomide within 1 year of screening Participants who have received treatment with immunoadsorption columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or DPenicillamine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Rheumatoid Arthritis (RA)</keyword>
</DOC>